



August 29, 2015

COR/2015/08-14

The General Manager
Karachi Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Subject: **Financial Results For The Year Ended June 30, 2015**

Dear Sir,

We have to inform you that the Board of Directors of our Company in their meeting held on August 29, 2015 at 2:00 P. M. at 197-A, The Mall, Rawalpindi, recommended the following:

CASH DIVIDEND

A final Cash Dividend for the year ended June 30, 2015 at Rs. 15.00 per share i.e. 150%. This is in addition to Interim Dividend already paid at Rs. 4.00 per share i.e. 40%.

The financial results of the Company are attached.

Company's individual and consolidated Profit and Loss Account for the year ended June 30, 2015 with comparison of corresponding year is enclosed.


The Annual General Meeting of the Company will be held on October 19, 2015 at 12:30 P.M. at Company's Registered Office 197-A, The Mall, Rawalpindi.

The above entitlement will be paid to the shareholders whose name will appear in the Register of Members on October 12, 2015.

The Share Transfer Books of the Company will be closed from October 13, 2015 to October 19, 2015 (both days inclusive). Transfers received at the Office of the Company's Share Registrar, CorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore at the close of business on October 12, 2015 will be treated in time for the purpose of above entitlement to the transferees.

We will be sending you 200 copies of printed accounts for distribution amongst the TRE Certificate Holders of the Exchange 21 days before the date of AGM.

Yours truly,


Syed Ghausuddin Saif
Company Secretary

Encl.



Head Office Biotech Factory:
S.H.M. Sunder Rawind Road
Rawind Lahore, Pakistan
Office phones: +92-42-36026200
Fax: +92-42-36026701 2
Factory phones: +92-309-5053135
Fax: +92-42-36026701

Registered Office:
197-A
The Mall Rawalpindi 46100
Pakistan
Phones: +92-51-4252155-57
Fax: +92-51-4252153

Pharma Factory:
PO Ferozsons
Amangath-Nowshera, (KPK)
Pakistan
Phones: +92-923-614295
+92-923-610159
Fax: +92-923-611302
+92-923-611547

Sales Office: Lahore
43-Al Noor Building,
Bank Square, The Mall,
Lahore, Pakistan.
Phones: +92-42-37358194
Fax: +92-42-37313680

Sales Office: Karachi
House No 9, Maghool Corporate
Society, Shabrah-e-Faisal Karachi,
Pakistan.
Phones: +92-21-34386852
Fax: +92-21-34386754

Ferozsons Laboratories Limited
 Unconsolidated Profit and Loss Account

For the year ended 30 June 2015

	Note	2015 Rupees	2014 Rupees
Revenue - net	23	4,433,552,219	2,534,928,325
Cost of sales	24	(2,417,655,623)	(1,231,294,748)
Gross profit		<u>2,015,896,596</u>	<u>1,303,633,577</u>
Administrative expenses	25	(192,837,874)	(160,493,145)
Selling and distribution expenses	26	(733,990,364)	(600,132,625)
Finance costs	27	(13,964,279)	(17,085,720)
Other expenses	28	(81,100,687)	(48,180,659)
Other income	29	88,535,346	89,333,419
Profit before taxation		<u>1,082,538,738</u>	<u>567,074,847</u>
Taxation	30	(333,948,031)	(149,546,613)
Profit after taxation		<u>748,590,707</u>	<u>417,528,234</u>
Earnings per share - basic and diluted	31	<u>24.80</u>	<u>13.83</u>

MMG 801

The annexed notes from 1 to 39 form an integral part of these unconsolidated financial statements.

Ferozsons Laboratories Limited
 Consolidated Profit and Loss Account
 For the year ended 30 June 2015

	Note	2015 Rupees	2014 Rupees
Revenue - net	19	5,705,868,875	3,831,560,333
Cost of sales	20	(3,114,691,589)	(2,003,510,028)
Gross profit		2,591,177,286	1,828,050,305
Administrative expenses	21	(218,229,954)	(196,185,011)
Selling and distribution expenses	22	(966,052,071)	(852,798,246)
Finance costs	23	(16,043,156)	(18,781,869)
Other expenses	24	(105,267,862)	(64,082,168)
Other income	25	74,026,186	64,516,505
Profit before taxation		1,359,610,429	760,719,516
Taxation	26	(415,822,452)	(208,556,709)
Profit after taxation		943,787,977	552,162,807
<i>Attributable to:</i>			
Owners of the Company		904,848,233	525,502,792
Non-controlling interests		38,939,744	26,660,015
Profit for the year		943,787,977	552,162,807

The annexed notes from 1 to 34 form an integral part of these consolidated financial statements.

10/11/15